Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.
As a medical student and researcher, I was shocked by the brazen inequity of the trial. Randomized controlled trials have ...
Prior experience with AI tools made no difference. The second study, from University of Pennsylvania's Wharton School, asked ...
Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...
Introduction Suicidal ideation is common in young people and increases the risk of suicide. Effective interventions that are relevant and accessible to young people, so-called digital natives, are ...
Partial meniscectomy does not improve patient symptoms or function, reveals a 10-year follow-up of the FIDELITY, a ...
At a Senate hearing on Wednesday, Robert F. Kennedy, Jr., referred to ibogaine as the most promising treatment for PTSD and ...
Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
Preeclampsia can be deadly in pregnancy, and aside from delivering the baby, the condition has no targeted treatment. A new ...
Telemonitoring heart failure programmes improved self-care and adherence in a clinical trial. Learn how digital care could ...
In October 2024, Calluna Pharma concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and ...
A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results